Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414871 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP1A2MAPK1SMN1; SMN2HPGD | |
| SCHEMBL2576954 | 0.97 | — | — | |
| SCHEMBL18124347 | 0.89 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9184856 | 0.85 | — | — | |
| Azepane SCHEMBL15135390 | 0.85 | CA2 (0.41) | ALDH1A1CA2CHKA | |
| SCHEMBL28844421 | 0.82 | — | — | |
| SCHEMBL5855885 | 0.81 | ALDH1A1 (0.36) | ALDH1A1CYP1A2MAPK1SMN1; SMN2HPGD | |
| SCHEMBL5597409 | 0.80 | HPGD (0.32) | ALDH1A1HPGD | |
| SCHEMBL2483464 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP1A2MAPK1SMN1; SMN2HPGD | |
| SCHEMBL1114107 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP1A2MAPK1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007081530-A2 | ENDOLUMINAL MEDICAL DEVICE FOR LOCAL DELIVERY OF CATHEPSIN INHIBITORS | MED INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| US-6380220-B1 | THERAPY OF NEURODEGENERATIVE DISEASES AND NEURONAL INJURIES WHICH ARE CASUED BY ISCHEMIA, TRAUMA OR MASSIVE HEMORRHAGES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | claimed |
| US-6046261-A | STABILIZER FOR ORGANIC MATERIAL HAVING EXCELLENT BLOOMING RESISTANCE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-04-04 | — | — | US | claimed |
| JP-11060556-A | — | — | None | — | — | JP | disclosed |
| JP-1193361-A | — | — | None | — | — | JP | disclosed |
| CN-109867676-A | Compound derived from a kind of pyrrolopyrimidine, pharmaceutical composition with and application thereof | 北京普祺医药科技有限公司 | 2019-06-11 | — | — | CN | disclosed |
| CN-106458969-A | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| CN-105518001-A | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG | 2016-04-20 | — | — | CN | disclosed |
| CN-105384694-A | Substituted aminopyrimidine derivative, preparation method therefor and pharmaceutical application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-03-09 | — | — | CN | disclosed |
| CN-104844566-A | Kinase inhibitor with novel structure | HEFEI INST PHYSICAL SCI CAS | 2015-08-19 | — | — | CN | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007081530-A2 | ENDOLUMINAL MEDICAL DEVICE FOR LOCAL DELIVERY OF CATHEPSIN INHIBITORS | MED INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-6380220-B1 | THERAPY OF NEURODEGENERATIVE DISEASES AND NEURONAL INJURIES WHICH ARE CASUED BY ISCHEMIA, TRAUMA OR MASSIVE HEMORRHAGES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| US-6380220-B1 | THERAPY OF NEURODEGENERATIVE DISEASES AND NEURONAL INJURIES WHICH ARE CASUED BY ISCHEMIA, TRAUMA OR MASSIVE HEMORRHAGES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| US-6046261-A | STABILIZER FOR ORGANIC MATERIAL HAVING EXCELLENT BLOOMING RESISTANCE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-04-04 | — | — | US | disclosed |
| CN-1239950-A | New derivates from piperidine-keto acid, their preparation and use | BASF AG (DE) | 1999-12-29 | — | — | CN | disclosed |
| JP-H1160556-A | PIPERIDINE-BASED COMPOUND, ITS PRODUCTION AND USE THEREOF | SUMITOMO CHEM CO LTD | 1999-03-02 | — | — | JP | disclosed |
| EP-0332761-A2 | Single-functional and mixtures of multifunctional oligomeric performance additive compositions, and their use | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1989-09-20 | — | — | EP | disclosed |
| JP-H01193361-A | STABILIZED SYNTHETIC RESIN COMPOSITION | ADEKA ARGUS CHEM CO LTD | 1989-08-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | ALDH1A1 3476/4885CYP1A2 3934/4885MAPK1 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.